Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407808 · ClinicalTrials.gov registry record · Phase 1
Cannabinoids, Learning, and Memory
A Phase 1 study of Cannabis and Psychotic Disorders, sponsored by Yale University.
- Active
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02407808: Active Phase 1 study of Cannabis and Psychotic Disorders, sponsored by Yale University.
NCT02407808 is a Phase 1 study of Cannabis and Psychotic Disorders that is active but no longer recruiting, run by Yale University. The registered enrollment target is 80 participants, below the 107-participant average among 24 other Cannabis trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02407808, a Phase 1 study of Cannabis and Psychotic Disorders, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.
Primary Outcome
a measure of verbal episodic memory
Conditions Studied
Interventions
- DRUG Placebo
- DRUG THC
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-02 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT02407808 still lists
NCT02407808 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 107-participant average among 24 other Cannabis trials with a reported enrollment target (25% lower).
The record links to 2 conditions, with Cannabis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02407808 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02407808 about?
NCT02407808 is a clinical study titled "Cannabinoids, Learning, and Memory". The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.
What is the current status of trial NCT02407808?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2015-02. Estimated completion is 2025-12.
What conditions does trial NCT02407808 study?
This clinical trial studies the following conditions: Cannabis, Psychotic Disorders.
What interventions are being tested in trial NCT02407808?
The interventions under investigation include: Placebo (DRUG), THC (DRUG).
Who is sponsoring clinical trial NCT02407808?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02407808 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02407808's enrollment target sits among peer trials
80 10th of 24 higher than 15 of 24 other Cannabis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans
RECRUITING · Phase 1
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
RECRUITING · Phase 1
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
RECRUITING · Phase 1
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
ACTIVE NOT RECRUITING · Phase 1
-
THC Memory & Reward Learning Pilot
ACTIVE NOT RECRUITING · Phase 1
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia